SCHEMBL1760979

SCHEMBL1760979

O=C(Cl)N1CCC(Oc2cccc(Cl)c2)CC1

nearest known ligand 0.63

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
EPHX2 P34913 7/20 0.63
SLC6A4 P31645 2/20 0.54
SLC6A2 P23975 1/20 0.54
SLC6A3 Q01959 1/20 0.54
CYP2C9 P11712 1/20 0.50
CYP2J2 P51589 1/20 0.50
KCNH2 Q12809 2/20 0.49
HRH3 Q9Y5N1 2/20 0.49
FPR2 P25090 1/20 0.48
PROKR1 Q8TCW9 1/20 0.48
OPRK1 P41145 2/20 0.48
HRH1 P35367 1/20 0.47
CCR3 P51677 1/20 0.47
HTR2C P28335 1/20 0.47
CNR1 P21554 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10608458 0.92 EPHX2 (0.57) EPHX2SLC6A4SLC6A2SLC6A3CYP2C9
SCHEMBL2932615 0.89 EPHX2 (0.63) EPHX2SLC6A4SLC6A2SLC6A3CYP2C9
SCHEMBL2636719 0.88 EPHX2 (0.56) EPHX2SLC6A4SLC6A2SLC6A3CYP2C9
SCHEMBL22278187 0.86 EPHX2 (0.57) EPHX2SLC6A4SLC6A2SLC6A3CYP2C9
SCHEMBL9450767 0.85 EPHX2 (0.53) EPHX2SLC6A4SLC6A2SLC6A3CYP2C9
SCHEMBL22173976 0.85 EPHX2 (0.56) EPHX2SLC6A4SLC6A2SLC6A3CYP2C9
SCHEMBL2636720 0.84 EPHX2 (0.55) EPHX2SLC6A4SLC6A2SLC6A3CYP2C9
SCHEMBL10964732 0.84 EPHX2 (0.55) EPHX2SLC6A4SLC6A2SLC6A3CYP2C9
SCHEMBL10606771 0.83 EPHX2 (0.60) EPHX2CYP2C9CYP2J2
SCHEMBL29731062 0.82 STS (0.57) EPHX2HRH3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101448844-B Thiazolo-pyramidine / pyridine urea derivatives as adenosine a2b receptor antagonists HOFFMANN LA ROCHE 2012-07-25 CN disclosed
US-7947692-B2 Substituted thiazolo[5,4-d]pyrimidine urea derivatives HOFFMANN-LA ROCHE INC. (US) 2011-05-24 US disclosed
EP-2027132-B1 THIAZOLO-PYRAMIDINE / PYRIDINE UREA DERIVATIVES AS ADENOSINE A2B RECEPTOR ANTAGONISTS HOFFMANN LA ROCHE (CH) 2010-09-15 EP disclosed
EP-2027132-A1 THIAZOLO-PYRAMIDINE / PYRIDINE UREA DERIVATIVES AS ADENOSINE A2B RECEPTOR ANTAGONISTS F.HOFFMANN-LA ROCHE AG (CH) 2009-02-25 EP disclosed
WO-2007134958-A1 THIAZOLO-PYRAMIDINE / PYRIDINE UREA DERIVATIVES AS ADENOSINE A2B RECEPTOR ANTAGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2007-11-29 WO disclosed
US-20070270433-A1 Thiazolo-pyrimidine/pyridine urea derivatives BRINKMAN JOHN A 2007-11-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070270433-A1 Thiazolo-pyrimidine/pyridine urea derivatives ADORA2B, UTS2R, TBXA2R EPHX2 1201/4885SLC6A4 1735/4885SLC6A2 2516/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.